FTC Fines Kubota Subsidiary $2 Million For `Made in USA' Labeling
By Dean Seal
The Federal Trade Commission has fined Kubota's North American business $2 million for allegedly mislabeling some of its replacement parts as being "Made in USA."
The agency said on Friday that since 2021, Kubota North America has falsely labeled thousands of replacement parts for its tractors and other equipment as being produced in the U.S. when they were actually made entirely overseas.
After the maker of tractors and agricultural equipment moved manufacturing for some parts to other countries it failed to update the products' labeling to reflect the change, according to the FTC's complaint.
Without admitting or denying the allegations, Kubota North America has agreed to pay a penalty and to be barred from making deceptive claims.
A spokesperson for Kubota didn't immediately respond to a request for comment.
The FTC said this is the largest settlement it has ever netted in a "Made in USA" case and that it previously sued Kubota in 1999 for similar alleged conduct. Kubota had been the subject of an FTC order related to that case until it expired in 2019
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 26, 2024 12:13 ET (17:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom